C-mo Medical Solutions has achieved a significant regulatory milestone by securing a CE Mark for its AI-powered cough monitoring platform, the C-mo System. This approval validates the non-invasive device for use in clinical research and medical practice across Europe. The technology promises to deliver precise, objective data on cough frequency and intensity, transforming how respiratory conditions are monitored.
A New Standard in Cough Monitoring
The C-mo System is designated as a Class IIa medical device under stringent European regulations. It integrates a wearable biosensor with sophisticated AI algorithms and a dedicated software platform. This comprehensive solution is designed to objectively measure key cough metrics for patients over five years of age.
A key differentiator of the system is its privacy-preserving design, which generates detailed cough data without recording private conversations. This approach addresses critical patient privacy concerns that have limited the adoption of other monitoring tools. It enables the collection of robust, longitudinal data essential for modern clinical assessments and research.
Rigorous Validation and Regulatory Approval
The CE Mark, granted under EU MDR 2017/745, builds upon C-mo's existing ISO 13485 certification for quality management. This latest approval reinforces the company's commitment to meeting the highest safety and performance standards. It officially clears the path for the system's broader commercial adoption throughout the European economic area.
The system's efficacy has been demonstrated in three clinical studies involving more than 180 participants. These trials yielded impressive results, showing a median sensitivity of 95.0% and a median specificity of 99.9% for cough detection. The technology performed consistently well across diverse patient groups, diseases, and body mass indexes.
Addressing a Critical Unmet Need
Respiratory diseases represent a growing global health challenge, with chronic cough affecting an estimated 9.6% of adults worldwide. This condition places a substantial burden on both individuals and healthcare systems. The lack of objective monitoring tools has historically hindered effective diagnosis, treatment, and long-term management.
Chronic cough significantly impairs quality of life, often leading to sleep disruption, anxiety, and depression. It is a primary symptom in numerous conditions, including idiopathic pulmonary fibrosis, COPD, and asthma. C-mo's technology provides a much-needed tool for accurately tracking this critical biomarker.
Commercial Strategy and Expert Endorsement
C-mo Medical Solutions is initially targeting the clinical trials market, where there is strong demand for objective cough endpoints. Pharmaceutical companies and research organizations can now leverage the system to gather more reliable data. The CE Mark also supports the company's long-term vision of integrating the device into routine medical practice.
Diogo Tecelão, CEO of C-mo, stated that the regulatory milestone reinforces confidence in the technology's quality and safety. He emphasized the company's goal to establish a new benchmark for objective cough assessment. The approval positions C-mo to effectively support researchers and healthcare professionals across various settings.
Professor Surinder Birring of King’s College Hospital highlighted the growing importance of precise cough analysis in respiratory research. He praised the C-mo System for its ability to objectively measure multiple cough dimensions with strong performance. This capability is particularly valuable for generating the robust endpoints required in clinical trials.
The CE certification for the C-mo System marks a pivotal moment for C-mo Medical Solutions and the broader field of respiratory medicine. By providing a precise, objective, and privacy-centric tool, the company is poised to enhance the quality of data in clinical trials. This innovation ultimately promises to improve the diagnosis and management of conditions where cough is a key indicator.